Showing results (11-20 of 211) with videos related to
Sort By:
Pageof 22
Current Opinion in Supportive and Palliative Care|December 21, 2023
Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathyDaniel L HertzPharmacogenomics|April 16, 2019
Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplantAmy L Pasternak, Kelley M Kidwell, Jacqueline M Dempsey, et al.Annual Review of Medicine|November 12, 2014
Pharmacogenetics of cancer drugsDaniel L Hertz, James RaeTransplantation and Cellular Therapy|September 28, 2021
Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral TherapyAmy L Pasternak, Lauren A Marcath, Yajing Li, et al.Handbook of Experimental Pharmacology|October 17, 2022
Chemotherapy-Induced Peripheral NeuropathyCiao-Sin Chen, Daniel L HertzClinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncologyDaniel L Hertz, Howard L McLeodJournal of Human Genetics|May 17, 2013
Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicityDaniel L Hertz, Howard L McLeodCancer Chemotherapy and Pharmacology|May 11, 2024
Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicityYuchen Sun, Yue Cheng, Daniel L HertzExpert Reviews in Molecular Medicine|November 21, 2008
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?Vered Stearns, James M RaeAmerican Journal of Epidemiology|December 19, 2016
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of HeterozygosityThomas P Ahern, Daniel L Hertz, Per Damkier, et al.Pageof 22